Compare ZG & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZG | PCVX |
|---|---|---|
| Founded | 2004 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5B | 7.0B |
| IPO Year | 2014 | 2020 |
| Metric | ZG | PCVX |
|---|---|---|
| Price | $31.79 | $62.04 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 25 | 11 |
| Target Price | $46.32 | ★ $117.30 |
| AVG Volume (30 Days) | 952.3K | ★ 3.7M |
| Earning Date | 11-04-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 118.75 | N/A |
| EPS | ★ 0.18 | N/A |
| Revenue | ★ $1,076,794,000.00 | N/A |
| Revenue This Year | $14.04 | N/A |
| Revenue Next Year | $11.77 | N/A |
| P/E Ratio | $178.11 | ★ N/A |
| Revenue Growth | ★ 27.19 | N/A |
| 52 Week Low | $27.25 | $39.87 |
| 52 Week High | $74.80 | $90.75 |
| Indicator | ZG | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 49.94 | 48.40 |
| Support Level | $31.30 | $52.91 |
| Resistance Level | $35.08 | $63.08 |
| Average True Range (ATR) | 1.42 | 3.00 |
| MACD | 0.12 | -0.57 |
| Stochastic Oscillator | 49.56 | 22.06 |
Zillow Group Inc is a real estate technology company offering a digital platform that connects real estate customers with sellers, agents, loan officers, and other real estate-related professionals. With its tools and resources, Zillow helps real estate professionals grow their businesses, and for renters and housing providers, it offers a marketplace along with a set of end-to-end products and services to streamline applications, leases, payments, and more. The group operates various brands such as Zillow, Zillow Home Loans, Zillow Rentals, Zillow New Construction, Trulia, StreetEasy, Out East, HotPads, Follow Up Boss, ShowingTime, dotloop, and Zillow Closing. Its ecosystem spans the entire home journey from shopping to renting, buying, selling, and financing real estate.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.